Liver enzymes in patients with chronic kidney disease undergoing peritoneal dialysis and hemodialysis

Clinics

Volumn 67, Issue 2, 2012, Pages 131-134

  de Oliveira Liberato, Isabella Ramos ^a   de Almeida Lopes, Edmundo Pessoa ^a   de Mattos Cavalcante, Maria Alina Gomes ^b   Pinto, Tiago Costa ^a   Moura, Izolda Fernades ^a   Loureiro, Luiz ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b Nefroclínica Dialysis Unit   (Brazil)

Author keywords

Alanine aminotransferase; Chronic renal failure; Hemodialysis; Liver enzymes; Peritoneal dialysis

Indexed keywords

EID: 84857672341     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(02)07     Document Type: Article

References (20)

1. Al-Wakeel J, Mailk GH, Al-Mohaya S, Mitwalli A, Baroudi F, El Gamal H, et al. Liver disease in dialysis patients with antibodies to hepatitis C virus. Nephrol Dial Transplant. 1996;11:2265-2268.
2. Yuki N, Ishida H, Inoue T, Tabata T, Matsushita Y, Sasaki Y, et al. Reappraisal of biochemical hepatitis C activity in hemodialysis patients. J Clin Gastroenterol. 2000;30:187-194, http://dx.doi.org/10.1097/00004836-200003000-00012.
3. Guh JY, Lai YH, Yang CY, Chen SC, Chuang WL, Hsu TC, et al. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients. Nephron. 1995;69:459-65, http://dx.doi.org/10.1159/000188520.
4. Yasuda K, Okuda K, Endo N, Ishiwatari Y, Ikeda R, Hayashi H, et al. Hypoaminotransferasemia in patients undergoing long-term hemodialysis: clinical and biochemical appraisal. Gastroenterology. 1995;109:1295-1300, http://dx.doi.org/10.1016/0016-5085(95)90591-X.
5. Lopes EP, Gouveia EC, Albuquerque ACC, Sette LH, Mello LA, Moreira RC, et al. Determination of the cutoff value of serum alanine aminotransferase in patients undergoing hemodialysis to identify biochemical activity in patients with hepatitis C viremia. J Clin Virol. 2006;35:298-302, http://dx.doi.org/10.1016/j.jcv.2005.09.010.
6. Fabrizi F, Lunghi G, Ganeshan SV, Martin P, Messa P. Hepatitis C virus infection and the dialysis patient. Semin Dial. 2007;20:416-422, http://dx.doi.org/10.1111/j.1525-139X.2007.00311.x.
7. Alberti A, Noventa F, Benvegnu L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Inter Med. 2002;137:961-4.
8. Fabrizi F, Lunghi G, Finazzi S, Colucci P, Pagano A, Ponticelli C, et al. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. Am J Kidney Dis. 2001;38:1009-15, http://dx.doi.org/10.1053/ajkd.2001.28590.
9. Ono K, Ono T, Matsumata T. The pathogenesis of decreased aspartate amino-transferase and alanine aminotransferase activity in the plasma of hemodialysis patients: the role of vitamin B6 deficiency. Clin Nephrol. 1995;43:405-8.
10. Lopes EP, Sette LH, Sette JB, Luna CF, Andrade AM, Moraes M, et al. Serum alanine aminotransferase levels, hematocrit rate and body weight correlations before and after hemodialysis session. Clinics (Sao Paulo). 2009;64:941-5.
11. Prati D, Taioli E, Zanella A, Torre ED, Butelli S, Vecchio ED, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Inter Med. 2002;137:1-9.
12. Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. Br Med J. 2004;328:983-6, http://dx.doi.org/10.1136/bmj.38050.593634.63.
13. Trevizoli JE, Menezes R, Velasco LF, Amorim R, de Carvalho MB, Mendes LS, et al. Hepatitis C is less aggressive in hemodialysis patients than in nonuremic patients. Clin J Am Soc Nephrol. 2008;3:1385-90, http://dx.doi.org/10.2215/CJN.01330308.
14. Hung KY, Lee KC, Yen KD, Tsai TJ, Che WY. Revised cut off values of serum aminotransferase in detecting viral hepatitis among CAPD patients: experience from Taiwan, an endemic area for hepatitis B. Nephrol Dial Transplant. 1997;12:180-3, http://dx.doi.org/10.1093/ndt/12.1.180.
15. Cotler SJ, Diaz G, Gundlapalli S, Jakate S, Chawla A, Mital D, et al. Characteristics of hepatitis C in renal transplant candidates. J Clin Gastroenterol. 2002;35:191-5, http://dx.doi.org/10.1097/00004836-200208000-00013.
16. Souza JF, Longui CA, Miorin LA, Sens YA. Gamma-glutamyltransferase activity in chronic dialysis patients and renal transplant recipients with hepatitis C virus infection. Transplant Proc. 2008;40:1319-23, http://dx.doi.org/10.1016/j.transproceed.2008.03.157.
17. Ferreira VS, Pernambuco RB, Lopes EP, Morais CN, Rodrigues MC, Arruda MJ, et al. Frequency and risk factors associated with non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Arq Bras Endocrinol Metabol. 2010;54:362-8, http://dx.doi.org/10.1590/S0004-27302010000400004.
18. Dummer CD, Thomé FS, Veronese FV. Doença renal crônica, inflamação e aterosclerose: Novos conceitos deumvelho problema. Rev Assoc Med Bras. 2007;53:446-50, http://dx.doi.org/10.1590/S0104-42302007000500022.
19. Fabrizi F, De Vecchi AF, Qureshi AR, Aucella F, Lunghi G, Bruchfeld A, et al. Gamma-glutamyltransferase activity and viral hepatitis in dialysis population. Int J Artif Organs. 2007;30:6-15.
20. Nishida C, Uto H, Oketani M, Tokunaga K, Nosaki T, Fukumoto M, et al. Clinical significance of alanine aminotransferase levels and the effect of ursodeoxycholic acid in hemodialysis patients with chronic hepatitis C. J Gastroenterol. 2010;45:326-334, http://dx.doi.org/10.1007/s00535-009-0149-0.